A previous study demonstrated that SLAMF1, SLAMF2, and SLAMF7 receptors are rather downregulated on CLL cells as compared to their normal B cell counterpart [12], suggesting that high expression of these molecules may have detrimental (e.g., antiproliferative) effects in the CLL context. Here, SLAMF1 is linked to B-cell chronic lymphocytic leukemia.